Textbook of personalized medicine:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
New York, NY
Springer
2009
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Hier auch später erschienene, unveränderte Nachdrucke |
| Beschreibung: | XXVI, 430 S. |
| ISBN: | 9781441907684 9781489983343 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV036466696 | ||
| 003 | DE-604 | ||
| 005 | 20150311 | ||
| 007 | t | ||
| 008 | 100525s2009 |||| 00||| eng d | ||
| 015 | |a 09,N21,1581 |2 dnb | ||
| 016 | 7 | |a 994035896 |2 DE-101 | |
| 020 | |a 9781441907684 |9 978-1-4419-0768-4 | ||
| 020 | |a 9781489983343 |c Paperback |9 978-1-4899-8334-3 | ||
| 024 | 3 | |a 9781441907684 | |
| 028 | 5 | 2 | |a 12644087 |
| 035 | |a (OCoLC)890706528 | ||
| 035 | |a (DE-599)DNB994035896 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-703 |a DE-19 |a DE-20 | ||
| 084 | |a YT 1300 |0 (DE-625)154156: |2 rvk | ||
| 084 | |a 660 |2 sdnb | ||
| 100 | 1 | |a Jain, Kewal K. |d 1937- |e Verfasser |0 (DE-588)114376093 |4 aut | |
| 245 | 1 | 0 | |a Textbook of personalized medicine |c Kewal K. Jain |
| 264 | 1 | |a New York, NY |b Springer |c 2009 | |
| 300 | |a XXVI, 430 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Hier auch später erschienene, unveränderte Nachdrucke | ||
| 650 | 0 | 7 | |a Pharmakogenetik |0 (DE-588)4271255-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Individualisierte Medizin |0 (DE-588)7660544-9 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Pharmakogenetik |0 (DE-588)4271255-5 |D s |
| 689 | 0 | 1 | |a Individualisierte Medizin |0 (DE-588)7660544-9 |D s |
| 689 | 0 | |5 DE-604 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |z 978-1-4419-0769-1 |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020338468&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-020338468 | ||
Datensatz im Suchindex
| _version_ | 1804142961693294592 |
|---|---|
| adam_text | Titel: Textbook of personalized medicine
Autor: Jain, Kewal K.
Jahr: 2009
Contents
Preface vii
1 Basics of Personalized Medicine 1
Definition of Personalized Medicine 1
History of Medical Concepts Relevant to Personalized Medicine 3
Molecular Biological Basis of Personalized Medicine 5
The Human Genome 6
Chromosomes 6
Genes 7
The Genetic Code 7
Gene Expression 8
DNA Sequences and Structure 8
Single Nucleotide Polymorphisms 9
Genotype and Haplotypes 9
Genetic Variations in the Human Genome 9
Insertions and Deletions in the Human Genome 10
Large Scale Variation in Human Genome 11
Variation in Copy Number in the Human Genome 11
Structural Variants in the Human Genome 12
Mapping and Sequencing of Structural Variants from
Human Genomes 13
1,000 Genomes Project 14
Human Variome Project 15
Basics Technologies for Developing Personalized Medicine 15
Definitions of Technologies Relevant to Personalized Medicine 15
Problems with the ICH Definitions of Pharmacogenomics
and Pharmacogenetics 16
Relationship of Various Technologies to Personalized Medicine 16
Conventional Medicine vs. Personalized Medicine 17
Genetic Basis of Personalized Medicine 18
Genetic Medicine 18
Human Disease and Genes 18
ix
x Contents
Genetic and Environmental Interactions in Etiology
of Human Diseases 19
Mass Analysis of DNA from Whole Populations 19
Role of Genetics in Development of Personalized Medicines 20
Genetic Databases 20
Genetic Epidemiology 21
Limitations of Medical Genetics and Future Prospects 22
Genetics vs. Epigenetics 22
Role of Systems Biology in Personalized Medicine 22
Systems Pharmacology 24
Systems Medicine 24
A Personalized Approach to Environmental Factors in Disease 25
Reclassification of Diseases 26
Summary 27
2 Molecular Diagnostics as Basis of Personalized Medicine 29
Introduction 29
Molecular Diagnostic Technologies 29
PNA Sequencing 30
piochips and Microarrays 30
DNA Biochip Technology for Developing Personalized Medicine 30
Role of Protein Biochips in Personalized Medicine 34
Cytogenetics 35
Molecular Cytogenetics as Basis for Personalized Medicine 35
Cytomics as a Basis for Personalized Medicine 36
SNP Genotyping 37
Technologies for SNP Analysis 37
Applications of SNPs Relevant to Personalized Medicine 37
Concluding Remarks on SNP Genotyping 39
ffeplotyping 40
HapMap Project 41
Predicting Drug Response with HapMap 42
f^anodiagnostics for Personalized Medicine 42
Cantilevers for Personalized Medical Diagnostics 43
Nanopore-Based Technology for Single Molecule Identification 44
Application of Proteomics in Molecular Diagnosis 44
Comparison of Proteomic and Genomic Approaches in
Personalized Medicine 44
Gene Expression Profiling 45
DMA Microarrays for Gene Expression Studies 46
Analysis of Single-Cell Gene Expression 47
Gene Expression Profiling Based on Alternative RNA Splicing 47
NJolecular Imaging and Personalized Medicine 48
Monitoring In Vivo Gene Expression by Molecular Imaging 49
Glycomics-Based Diagnostics 49
Contents xi
Combination of Diagnostics and Therapeutics 50
Point-of-Care Diagnosis 50
Point-of-Care Diagnosis of Infections 52
Advantages vs. Disadvantages of Point-of-Care Diagnosis 52
Future Prospects of Point-of-Care Diagnosis 53
Genetic Testing for Disease Predisposition 53
Personal Genetic Service 54
Role of Diagnostics in Integrated Healthcare 54
Concept of Integrated Healthcare 54
Components of Integrated Healthcare 55
Screening 55
Disease Prediction 55
Early Diagnosis 55
Prevention 56
Therapy Based on Molecular Diagnosis 56
Monitoring of Therapy 56
Advantages and Limitations of Integrated Healthcare 56
Future of Molecular Diagnostics in Personalized Medicine 57
Summary 57
3 Role of Biomarkers in Personalized Medicine 59
Introduction 59
Technologies for Discovery of Biomarkers 60
Systems Biology Approach to Biomarker Identification 60
Epigenomic Technologies 60
Discovery of Methylation Biomarkers 62
Proteomic Strategies for Biomarker Identification 62
Proteomic Technologies for Detection of Biomarkers
in Body Fluids 63
Biomarkers for Diagnostics 63
Biomarkers for Drug Development 64
Use of Biomarkers for Developing MAb Therapy in Oncology 64
Biobanking, Biomarkers and Personalized Medicine 65
Expression Signatures as Diagnostic/Prognostic Tools 66
Biomarkers for Monitoring Response to Therapy 66
Drug Rescue by Biomarker-Based Personalized Medicine 67
Future Role of Biomarkers in Personalized Medicine 68
Summary 68
4 Pharmacogenetics 69
Basics of Pharmacogenetics 69
Role of Molecular Diagnostics in Pharmacogenetics 70
Role of Pharmacogenetics in Pharmaceutical Industry 71
Study of the Drug Metabolism and Pharmacological Effects 71
Causes of Variations in Drug Metabolism 72
xj; Contents
Enzymes Relevant to Drug Metabolism 72
Pharmacogenetics of Phase I Metabolism 73
Cyp450 73
P450 CYP 2D6 Inhibition by Selective Serotonin Reuptake
Inhibitors (SSRIs) 75
Cytochrome P450 Polymorphisms and Response to Clopidogrel 76
Lansoprazole and Cytochrome P450 76
Glucose-6-Phosphate Dehydrogenase 77
Pharmacogenetics of Phase II Metabolism 78
./V-Acetyltransferase 78
Uridine Diphosphate-Glucuronosyltransferase 79
Measurement of CYP Isoforms 79
Polymorphism of Drug Transporters 80
Genetic Variation in Drug Targets 81
Polymorphisms of Kinase Genes 82
Effect of Genetic Polymorphisms on Response of Disease to Drugs 82
Ethnic Differences in Drug Metabolism 83
Gender Differences in Pharmacogenetics 83
Role of Pharmacogenetics in Drug Safety 84
Adverse Drug Reactions 84
ADRs in Children 84
Genetically Determined ADRs 85
ADRs of Chemotherapy 86
Malignant Hyperthermia 87
Pharmacogenetics of Clozapine-Induced Agranulocytosis 87
Role of Pharmacogenetics in Warfarin Therapy 88
Role of Pharmacogenetics in Carbamazepine Therapy ¦.. 89
Role of Pharmacogenetics in Statin Therapy 89
FDA Consortium for Genetic Biomarkers of Serious
Adverse Events 90
Therapeutic Drug Monitoring, Phenotyping, and Genotyping 91
Therapeutic Drug Monitoring 91
Phenotyping 91
Genotyping 93
Genotyping vs. Phenotyping 93
Phenomics 94
Limitations of Genotype-Phenotype Association Studies 95
Molecular Toxicology in Relation to Personalized Medicines 95
Toxicogenomics 95
Gene Expression Studies 96
Genomics and the Prediction of Xenobiotic Toxicity 97
Pharmacogenetics in Clinical Trials 97
Clinical Implications of Pharmacogenetics 98
Application of CYP450 Genotyping in Clinical Practice 98
Genotype-Based Drug Dose Adjustment 98
Contents xiii
Examples of use of Pharmacogenetics in Clinical Pharmacology 99
Linking Pharmacogenetics with Pharmacovigilance 100
Genetic Susceptibility to ADRs 100
Linking Genetic Testing to Postmarketing ADR Surveillance 100
Recommendations for the Clinical Use of Pharmacogenetics 101
Limitations of Pharmacogenetics 101
Future Role of Pharmacogenetics in Personalized Medicine 102
Summary 102
5 Pharmacogenomics 105
Introduction 105
Basics of Pharmacogenomics 105
Pharmacogenomics and Drug Discovery 107
Preclinical Prediction of Drug Efficacy 108
Pharmacogenomics and Clinical Trials 109
Impact of Genetic Profiling on Clinical Studies 109
Limitations of the Pharmacogenomic-Based Clinical Trials 111
Pharmacogenomic Aspects of Major Therapeutic Areas 112
Oncogenomics 112
Oncogenes 112
Tumor Suppressor Genes 113
Cardiogenomics 113
Neurogenomics 117
Pharmacogenomics of AD 117
Pharmacogenomics of Depression 118
Pharmacogenomics of Schizophrenia 118
Summary 119
6 Role of Pharmacoproteomics 121
Basics of Proteomics 121
Proteomic Approaches to the Study of Pathophysiology of Diseases 122
Single Cell Proteomics for Personalized Medicine 122
Diseases Due to Misfolding of Proteins 123
Therapies for Protein Misfolding 123
Significance of Mitochondrial Proteome in Human Disease 124
Proteomic Technologies for Drug Discovery and Development 125
Role of Reverse-Phase Protein Microarray in Drug Discovery 125
Role of Proteomics in Clinical Drug Safety 125
Toxicoproteomics 126
Application of Pharmacoproteomics in Personalized Medicine 128
Summary 128
7 Role of Metabolomics in Personalized Medicine 129
Metabolomics and Metabonomics 129
Metabolomics Bridges the Gap Between Genotype and Phenotype 130
xjv Contents
Metabolomics, Biomarkers and Personalized Medicine 131
Metabolomic Technologies 131
Urinary Profiling by Capillary Electrophoresis 132
Lipid Profiling 133
Role of Metabolomics in Biomarker Identification
and Pattern Recognition 133
Validation of Biomarkers in Large-Scale Human Metabolomics
Studies 134
Pharmacometabonomics 13^
Metabonomic Technologies for Toxicology Studies 135
Metabonomics/Metabolomics and Personalized Nutrition 136
Summary 136
8 Personalized Biological Therapies 137
Introduction 137
Recombinant Human Proteins 137
Therapeutic Monoclonal Antibodies 138
Cell Therapy 138
Autologous Tissue and Cell Transplants 139
Stem Cells 139
Role of Stem Cells Derived from Unfertilized Embryos 139
Cloning and Personalized Cell Therapy 140
Use of Stem Cells for Drug Testing 140
Gene Therapy 140
Personalized Vaccines 141
Personalized Vaccines for Viral Diseases 141
Personalized Cancer Vaccines 142
Patient-Specific Cancer Vaccines 142
Antigen-Specific Vaccines 143
Autologous Cell Vaccines 143
Personalized Melanoma Vaccines 145
Antisense Therapy 145
RNA Interference 146
MicroRNAs 146
Summary 147
9 Development of Personalized Medicine 149
Introduction 149
Non-genomic Factors in the Development of Personalized Medicine 150
Personalized Medicine Based on Circadian Rhythms 150
Intestinal Microflora 151
Gut Microbiome Compared to Human Genome 151
Metabolic Interactions of the Host and the Intestinal Microflora 152
Role of Drug Delivery in Personalized Medicine 152
Role of Molecular Imaging in Personalized Medicine 153
Contents xv
Personalized Approach to Clinical Trials 153
Use ofBayesian Approach in Clinical Trials 153
Individualizing Risks and Benefits in Clinical Trials 154
Clinical Trials of Therapeutics and Companion Diagnostics 155
Role of Genetic Banking Systems and Databases 155
Role of Biobanks in the Development of Personalized Medicine 155
UKBiobank 156
Biobanking and Development of Personalized
Medicine in the EU 156
CARTaGENE for Biobanks in Canada 157
Personalized Medicine Based on PhysioGenomics™ Technology 158
Role of Bioinformatics in Development of Personalized Medicine 159
Health Information Management 160
Electronic Health Records 160
Linking Patient Medical Records and Genetic Information 161
Management of Personal Genomic Data 162
Personalized Prognosis of Disease 162
Integration of Technologies for Development
of Personalized Medicine 163
Summary 163
10 Personalized Therapy for Cancer 165
Introduction 165
Challenges of Cancer Classification 165
Relationships of Technologies for Personalized
Management of Cancer 166
Impact of Molecular Diagnostics on the Management of Cancer 167
Analysis of RNA Splicing Events in Cancer 167
Analysis of Chromosomal Alterations in Cancer Cells 168
Cancer Classification Using Microarrays 168
Detection of Loss of Heterozygosity (LOH) 169
Diagnosis of Cancer of an Unknown Primary 170
Diagnostics for Detection of Minimal Residual Disease (MRD) 170
Fluorescent In Situ Hybridization 171
Gene Expression Profiling 171
Gene Expression Profiles Predict Chromosomal
Instability in Tumors 172
Isolation and Characterization of Circulating Tumor Cells (CTCs) 173
Modulation of CYP450 Activity for Cancer Therapy 173
Personalized Therapies Based on Oncogenic Pathway Signatures 174
Role of Molecular Imaging in Personalized Therapy of Cancer 175
Molecular Imaging for Personalized Drug
Development in Oncology 175
Molecular Imaging as Guide to Cancer Treatment 176
Functional Diffusion MRI 177
xvj Contents
Role of FDG-PET/CT in Personalizing Cancer Treatment 178
Tumor Imaging and Elimination by Targeted Gallium Corrole 179
Unraveling the Genetic Code of Cancer 179
Cancer Prognosis 180
Detection of Mutations for Risk Assessment and Prevention 181
Impact of Biomarkers on Management of Cancer 181
Predictive Biomarkers for Cancer 181
HER-2/neu Oncogene as a Biomarker for Cancer 182
L-asparaginase (L-ASP)Treatment of Cancer Guided
by a Biomarker 582
Determination of Response to Therapy 183
Phenotype-Based Cell Culture Assays 183
Ex Vivo Testing of Tumor Biopsy for Chemotherapy Sensitivity 183
Genomic Approaches to Predict Response to Anticancer Agents 184
Gene Expression Patterns to Predict Response
of Cancer to Therapy 184
Genomic Analysis of Tumor Biopsies 184
Mutation Detection at Molecular Level 185
Role of Genetic Variations in Susceptibility
to Anticancer Drugs 185
Proteomic Analysis of Tumor Biopsies to Predict Response
to Treatment 185
Real-time Apoptosis Monitoring 186
Serum Nucleosomes as Indicators of Sensitivity to Chemotherapy 186
Targeted Microbubbles to Tumors for Monitoring
Anticancer Therapy 187
Tissue Systems Biology Approach to Personalized
Management of Cancer 188
Targeted Cancer Therapies 188
Targeting Glycoproteins on Cell Surface 188
Targeting Pathways in Cancer 189
Functional Antibody-Based Personalized Therapies 189
Personalized Radiation Therapy 190
Molecular Diagnostics Combined with Cancer Therapeutics 191
Aptamers for Combined Diagnosis and Therapeutics of Cancer 192
I Role of Nanobiotechnology in Personalized Management of Cancer 192
I Design of Future Cancer Therapies 193
Screening for Personalized Anticancer Drugs 194
Role of Epigenetics in Development of Personalized
Cancer Therapies 194
Personalized Therapy of Cancer Based on Cancer Stem Cells 195
Role of Oncoproteomics in Personalized Therapy of Cancer 195
Cancer Tissue Proteomics 196
Pharmacogenomic-Based Chemotherapy 197
Whole Genome Technology to Predict Drug Resistance 197
Contents xvii
Anticancer Drug Selection Based on Molecular Characteristics
of Tumor 197
Testing Microsatellite-Instability for Response to Chemotherapy 198
Pharmacogenetics of Cancer Chemotherapy 199
CYP1A2 199
Thiopurine Methyltransferase 200
Dihydropyrimidine Dehydrogenase 201
UGT1A1 Test as Guide to Irinotecan Therapy 201
Role of Computational Models in Personalized Anticancer Therapy 202
A Computational Model of Kinetically Tailored Treatment 202
Mathematical Modeling of Tumor Microenvironments 202
Molecular Profiling of Cancer 203
Drug Resistance in Cancer 204
Detection of Drug Resistance in Cancer by Metabolic Profiling 205
Determination of Chemotherapy Response
by Topoisomerase Levels 205
A Systems Biology Approach to Drug Resistance in CRC 206
Management of Drug Resistance in Leukemia 206
Overexpression of Multidrug Resistance Gene 207
P53 Mutations 207
A Chemogenomic Approach to Drug Resistance 208
Examples of Personalized Management of Cancer 208
Personalized Management of Breast Cancer 208
Genetic Testing in Breast Cancer as a Guide to Treatment 209
Pharmacogenetics of Breast Cancer 210
Molecular Diagnostics in Breast Cancer 210
Racial Factors in the Management of Breast Cancer 212
Proteomics-Based Personalized Management of Breast Cancer 212
Tests for Prognosis of Breast Cancer 213
Developing Personalized Drugs for Breast Cancer 215
Developing Personalized Drugs for Triple-Negative
Breast Cancer 216
Predicting Response to Chemotherapy in Breast Cancer 216
Prediction of Resistance to Therapy in Breast Cancer 219
Prediction of Adverse Reaction to RT in Breast Cancer 220
Prediction of Recurrence in Breast Cancer for
Personalizing Therapy 220
TAILORx (Trial Assigning Individualized Options
for Treatment) 222
Gene Expression Plus Conventional Predictors
of Breast Cancer 223
iuture Development of Gene Expression Microarrays
for Breast Cancer 224
Personalized Management of Ovarian Cancer 224
Personalized Management of Hematological Malignancies 227
xviii Contems
Personalized Management of Acute Leukemias 227
Personalized Management of Chronic Lymphocytic Leukemia 229
Personalized Management of Multiple Myeloma (MM) 229
Personalized Management B Cell Lymphomas 231
Personalized Vaccine for Follicular Lymphoma 231
Personalized Management of Myelodysplasia 232
Personalized Management of Malignant Melanoma 232
Personalized Management of Gastrointestinal Cancer 232
Personalized Management of Esophageal Cancer 232
Personalized Management of CRC 233
Personalized Management of Lung Cancer 236
Determination of Outcome of EGFR Tyrosine Kinase
Inhibitor Treatment 236
Testing for Response to Chemotherapy in Lung Cancer 239
Testing for Prognosis of NSCLC 239
Testing for Recurrence of Lung Cancer 240
Role of a New Classification System in the Management
of Lung Cancer 240
Personlized Management of Prostate Cancer 241
Benefit of Lifestyle Changes Shown by Gene
Expression Studies 241
Personalized Management of Brain Cancer 242
Genetics and Genomics of Brain Cancer 242
Molecular Diagnostics for Personalized Management
of Brain Cancer 244
Personalized Chemotherapy of Brain Tumors 246
Biosimulation Approach to Personalizing Treatment
of Brain Cancer 247
Personalized Therapy of Oligodendroglial Tumors 248
Personalized Therapy of Neuroblastomas 249
Personalized Management of Germ Cell Brain Tumors 250
Future of Cancer Therapy 250
Challenges for Developing Personalized Cancer Therapies 250
The Cancer Genome Atlas 251
Role of the International Cancer Genome Consortium 251
Using Computer and Imaging Technologies
to Personalize Cancer Treatment 253
Integrated Genome-Wide Analysis of Cancer for
Personalized Therapy 253
Summary 254
11 Personalized Management of Neurological Disorders 255
Introduction 255
Personalized Drug Development for Neurological Disorders 255
Personalized Drug Discovery 255
Contents xix
Molecular Imaging and CNS Drug Development 255
Personalized Management of AD 257
Personalized Management of PD 258
Discovery of Subgroup-Selective Drug Targets in PD 259
Personalized Management of Epilepsy 259
Choice of the Right AED 260
Pharmacogenetics of Epilepsy 260
Pharmacogenomics of Epilepsy 261
Drug Resistance in Epilepsy 262
Future Prospects for Epilepsy 263
Personalized Management of Migraine 264
Personalized Treatment of MS 264
MBP8298 265
Pharmacogenomics of IFN-P Therapy in MS 266
Future Prospects of Personalized Therapy of MS 267
Personalized Management of Psychiatric Disorders 267
Psychopharmacogenetics 267
COMT Genotype and Response to Amphetamine 268
Genotype and Response to Methylphenidate in
Children with ADHD 268
Personalized Antipsychotic Therapy 269
Personalized Antidepressant Therapy 272
Pretreatment EEG to Predict Adverse Effects to Antidepressants.... 273
Individualization of SSRI Treatment 273
Vilazodone with a Test for Personalized Treatment
of Depression 275
Summary 275
12 Personalized Therapy of Cardiovascular Diseases 277
Introduction 277
Role of Cardiovascular Diagnostics in Personalized Management 277
Testing in Coronary Heart Disease 277
SNP Genotyping in Cardiovascular Disorders 278
Cardiovascular Disorders with a Genetic Component 279
Gene Variant as a Risk Factor for Sudden Cardiac Death 281
SNP Chip for Study of Cardiovascular Diseases 282
Pharmacogenomics of Cardiovascular Disorders 282
Modifying the Genetic Risk for MI 283
Management of Heart Failure 283
P-Blockers 283
Bucindolol 284
BiDil 284
Management of Hypertension 285
Pharmacogenomics of Diuretic Drugs 286
Pharmacogenomics of ACE Inhibitors 287
xx Contents
Management of Hypertension by Personalized Approach 287
Pharmacogenetics of Lipid-Lowering Therapies 288
Polymorphisms in Genes Involved in Cholesterol Metabolism 288
Role of eNOS Gene Polymorphisms 289
The STRENGTH Study 290
Personalized Management of Women with Hyperlipidemia 291
Thrombotic Disorders 291
Factor V Leiden Mutation 291
Anticoagulant Therapy 292
Nanotechnology-Based Personalized Therapy of
Cardiovascular Diseases 293
Project euHeart for Personalized Management of
Cardiovascular Diseases 294
Concluding Remarks 294
Summary 295
13 Personalized Management of Miscellaneous Disorders 297
Management of Viral Infections 297
Management of HIV 297
Genetics of Human Susceptibility to HIV Infection 297
Pharmacogenomics of Antiretroviral Agents 298
Role of Diagnostic Testing in HIV 299
CD4 Counts as a Guide to Drug Therapy for AIDS 299
Drug-Resistance in HIV 299
Measurement of Replication Capacity 300
Prevention of Adverse Reactions to Antiviral Drugs 300
Role of Genetic Variations in Susceptibility to HIV-1 301
Pharmacogenetics and HIV Drug Safety 302
Treatment of Hepatitis B 302
Treatment of Hepatitis C 302
Personalized Management of Tuberculosis (TB) 304
Personalized Management of Skin Disorders 305
Personalized Therapy of Rheumatoid Arthritis (RA) 305
DIATSTAT™ Anti-Cyclic Citrullinated Peptides in RA 307
Personalization of COX-2 Inhibitor Therapy 307
Personalization of Infliximab Therapy 308
Personalized Therapy of Asthma 308
Genetic Polymorphism and Response to /J,-Adrenergic Agonists 308
Genotyping in Asthma 309
Personalized Approaches in Immunology 310
Pharmacogenetics and Pharmacogenomics of
Immunosuppressive Agents 311
Personalized Immunosuppressant Therapy in Organ Transplants 311
Personalized Management of Pain 312
Pharmacogenetics/Pharmacogenomics of Pain 313
Contents xxi
Mechanism-Specific Management of Pain 314
Preoperative Testing to Tailor Postoperative
Analgesic Requirements 314
Personalized Analgesics 315
Management of Genetic Disorders 316
Personalized Treatment of Cystic Fibrosis 316
Personalized Management of Gastrointestinal Disorders 317
Personalized Therapy of Inflammatory Bowel Disease 317
Personalized Management of Lactose Intolerance 318
Personalized Approach to Addiction 318
Genetic Polymorphism and Management of Alcoholism 318
Personalized Therapy for Smoking Cessation., 319
Antidepressant Therapy for Smoking Cessation 319
Effectiveness of Nicotine Patches in Relation to Genotype 319
Personalized Approach to Drug Addiction 320
Personalized Approaches to Miscellaneous Problems 320
Hormone Replacement Therapy in Women 320
Personalized Treatment of Malaria 321
Personalized Management of Renal Disease 322
Personalization of Organ Transplantation 322
Personalization of Kidney Transplantation 323
Personalization of Cardiac Transplantation 323
Prediction of Rejection to Tailor Anti-Rejection Medications 324
Role of Immunological Biomarkers in Monitoring
Grafted Patients 325
Improved Matching of Blood Transfusion 325
Personalized Care of Trauma Patients 326
Personalized Anticoagulation 326
Personalized Hyperbaric Oxygen Therapy 327
Summary 328
14 Personalized Preventive Medicine 329
Introduction 329
Personalized Nutrition 330
Nutrigenomics 330
Nutrigenomics and Functional Foods 331
Nutrigenomics and Personalized Medicine 332
Nutrition and Proteomics 332
Personalized Diet Prescription 333
Summary 333
15 Organization of Personalized Medicine 335
Players in the Development of Personalized Medicine 335
Personalized Medicine Coalition 335
Role of Pharmaceutical Industry 336
xxjv Contents
Reducing the Cost Incurred by Adverse Drug Reactions 392
Overall Impact of Personalized Medicine on Healthcare 392
Summary 392
18 Future of Personalized Medicine 395
Introduction 395
Ongoing Genomic Projects 396
Understanding the Genetic Basis of Diseases 396
Personal Genome Project 396
Genome-Wide Association Studies 397
The 1000 Genomes Project 398
Genomics of Aging in a Genetically Homogeneous Population 399
Translational Science and Personalized Medicine 399
Translation of Genomic Research into Genetic Testing
for Healthcare 399
Long-Term Behavioral Effects of Personal Genetic Testing 400
Drivers for the Development of Personalized Medicine 401
Evolution of Medicine as a Driver for Personalized
Therapy Markets 402
Personalized Predictive Medicine 402
Opportunities and Challenges 403
Prospects and Limitations of Genetic Testing 403
Challenges in Delivery of Personalized Medicine 404
Pharmacotyping 405
Concluding Remarks about the Future of Personalized Medicine 405
Summary 406
References 407
Index 421
|
| any_adam_object | 1 |
| author | Jain, Kewal K. 1937- |
| author_GND | (DE-588)114376093 |
| author_facet | Jain, Kewal K. 1937- |
| author_role | aut |
| author_sort | Jain, Kewal K. 1937- |
| author_variant | k k j kk kkj |
| building | Verbundindex |
| bvnumber | BV036466696 |
| classification_rvk | YT 1300 |
| ctrlnum | (OCoLC)890706528 (DE-599)DNB994035896 |
| discipline | Chemie / Pharmazie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01656nam a2200433 c 4500</leader><controlfield tag="001">BV036466696</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20150311 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">100525s2009 |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">09,N21,1581</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">994035896</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781441907684</subfield><subfield code="9">978-1-4419-0768-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781489983343</subfield><subfield code="c">Paperback</subfield><subfield code="9">978-1-4899-8334-3</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9781441907684</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">12644087</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)890706528</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB994035896</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-703</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YT 1300</subfield><subfield code="0">(DE-625)154156:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">660</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jain, Kewal K.</subfield><subfield code="d">1937-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)114376093</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Textbook of personalized medicine</subfield><subfield code="c">Kewal K. Jain</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Springer</subfield><subfield code="c">2009</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXVI, 430 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Hier auch später erschienene, unveränderte Nachdrucke</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakogenetik</subfield><subfield code="0">(DE-588)4271255-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Individualisierte Medizin</subfield><subfield code="0">(DE-588)7660544-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Pharmakogenetik</subfield><subfield code="0">(DE-588)4271255-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Individualisierte Medizin</subfield><subfield code="0">(DE-588)7660544-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="z">978-1-4419-0769-1</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020338468&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-020338468</subfield></datafield></record></collection> |
| id | DE-604.BV036466696 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T22:40:04Z |
| institution | BVB |
| isbn | 9781441907684 9781489983343 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-020338468 |
| oclc_num | 890706528 |
| open_access_boolean | |
| owner | DE-703 DE-19 DE-BY-UBM DE-20 |
| owner_facet | DE-703 DE-19 DE-BY-UBM DE-20 |
| physical | XXVI, 430 S. |
| publishDate | 2009 |
| publishDateSearch | 2009 |
| publishDateSort | 2009 |
| publisher | Springer |
| record_format | marc |
| spelling | Jain, Kewal K. 1937- Verfasser (DE-588)114376093 aut Textbook of personalized medicine Kewal K. Jain New York, NY Springer 2009 XXVI, 430 S. txt rdacontent n rdamedia nc rdacarrier Hier auch später erschienene, unveränderte Nachdrucke Pharmakogenetik (DE-588)4271255-5 gnd rswk-swf Individualisierte Medizin (DE-588)7660544-9 gnd rswk-swf Pharmakogenetik (DE-588)4271255-5 s Individualisierte Medizin (DE-588)7660544-9 s DE-604 Erscheint auch als Online-Ausgabe 978-1-4419-0769-1 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020338468&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Jain, Kewal K. 1937- Textbook of personalized medicine Pharmakogenetik (DE-588)4271255-5 gnd Individualisierte Medizin (DE-588)7660544-9 gnd |
| subject_GND | (DE-588)4271255-5 (DE-588)7660544-9 |
| title | Textbook of personalized medicine |
| title_auth | Textbook of personalized medicine |
| title_exact_search | Textbook of personalized medicine |
| title_full | Textbook of personalized medicine Kewal K. Jain |
| title_fullStr | Textbook of personalized medicine Kewal K. Jain |
| title_full_unstemmed | Textbook of personalized medicine Kewal K. Jain |
| title_short | Textbook of personalized medicine |
| title_sort | textbook of personalized medicine |
| topic | Pharmakogenetik (DE-588)4271255-5 gnd Individualisierte Medizin (DE-588)7660544-9 gnd |
| topic_facet | Pharmakogenetik Individualisierte Medizin |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020338468&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT jainkewalk textbookofpersonalizedmedicine |